Sana Biotechnology

Compare

767 Followers

SANA Stock Chart & Stats

$4.90

$3.38(204.85%)

At close: Jan 08 4:00 PM EST

$4.90

$3.38(204.85%)

Day’s Range― - ―

52-Week Range$1.26 - $7.30

Previous CloseN/A

Volume118.31M

Average Volume (3M)5.80M

Market Cap

$1.27B

Enterprise Value$659.48M

Total Cash (Recent Filing)$72.67M

Total Debt (Recent Filing)$85.49M

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Nov 05, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding258,702,030

10 Day Avg. Volume6,382,315

30 Day Avg. Volume5,802,905

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.52

Enterprise Value/Revenue43.15

Enterprise Value/Gross Profit907.12

Enterprise Value/Ebitda-2.71

Forecast

1Y Price Target

$9.00

Price Target Upside83.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Advanced Development ProgramsSana is the only publicly-traded SMID-cap company with a wholly-owned in vivo CAR-T program in advanced development, offering scarcity value and considerable upside due to its flexible payload capacity and selective targeting abilities.

Innovative TreatmentsSana Biotechnology is developing a first-in-class hypoimmune candidate that does not require immunosuppression, allowing patients to maintain physiologic insulin production and functional immune protection.

Regulatory ProgressThe positive feedback from the FDA INTERACT meeting substantially raises the probability of success for the company's program.

Bears Say

Financial PerformanceSana reported a GAAP net loss of $93.8MM for Q2.

Sana Biotechnology News

Sana Biotechnology price target raised to $8 from $5 at Citizens JMP

Citizens JMP raised the firm’s price target on Sana Biotechnology (SANA) to $8 from $5 and keeps an...

2d ago

SANA

Sana Biotechnology strength attributed to EMJ Capital long call

Shares of Sana Biotechnology (SANA) are up $1.28, or 29% to $5.73 in afternoon trading after EMJ Capital’s...

17d ago

SANA

Sana Biotechnology Advances CAR-T Therapy with SC262 in Non-Hodgkin’s Lymphoma Study

Sana Biotechnology, Inc. (($SANA)) announced an update on their ongoing clinical study. Study Overview: Sana Biotechnology, Inc. is...

5d ago

SANA

Sana Biotechnology’s SC291 Study: A Promising Step in Autoimmune Disease Treatment

Sana Biotechnology, Inc. (($SANA)) announced an update on their ongoing clinical study. Study Overview: Sana Biotechnology, Inc. is...

5d ago

SANA

Wedbush bullish on Sana Biotechnology, initiates with an Outperform

As previously reported, Wedbush initiated coverage of Sana Biotechnology (SANA) with an Outperform rating and $5 price target...

1M ago

SANA

Sana Biotechnology initiated with an Outperform at Wedbush

Wedbush initiated coverage of Sana Biotechnology (SANA) with an Outperform rating and $5 price target Published first on...

1M ago

SANA

Sana Biotechnology Announces Leadership Transition

The latest update is out from Sana Biotechnology ( ($SANA) ). Sana Biotechnology announced the planned retirement of...

2M ago

SANA

Sana Biotechnology Board Member Resigns Effective August 29

Sana Biotechnology ( ($SANA) ) has issued an update. On August 28, 2025, Mary Agnes Wilderotter announced her...

2M ago

SANA

Sana Biotechnology Reports Q2 2025 Financial Results

Sana Biotechnology, Inc. ( ($SANA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

SANA

Sana Biotechnology’s Strategic Advances and Positive FDA Feedback Bolster Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on SANA stock, giving a Buy rating today....

3M ago

SANA

Sana Biotechnology’s Promising Advances in Diabetes Treatment and Strong Financial Position Support Buy Rating

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Sana Biotechnology, with...

3M ago

SANA

Sana Biotechnology reports Q2 EPS (16c), consensus (21c)

Reports Q2 cash, cash equivalents, and marketable securities of $72.7M. The company notes that its pro forma Q2...

3M ago

SANA

Sana Biotechnology options imply 10.8% move in share price post-earnings

Pre-earnings options volume in Sana Biotechnology (SANA) is normal with calls leading puts 19:1. Implied volatility suggests the...

3M ago

SANA

Why Is Sana Biotechnology Stock Down 25% Today?

Sana Biotechnology stock fell hard on Thursday after the company announced the price of shares in a public offering. ...

3M ago

SANA

SANA FAQ

What was Sana Biotechnology’s price range in the past 12 months?

Sana Biotechnology lowest stock price was $1.26 and its highest was $7.30 in the past 12 months.

What is Sana Biotechnology’s market cap?

Sana Biotechnology’s market cap is $1.27B.

When is Sana Biotechnology’s upcoming earnings report date?

Sana Biotechnology’s upcoming earnings report date is Nov 05, 2025 which is in 4 days.

How were Sana Biotechnology’s earnings last quarter?

Sana Biotechnology released its earnings results on Aug 11, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.201 by -$0.189.

Is Sana Biotechnology overvalued?

According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sana Biotechnology pay dividends?

Sana Biotechnology does not currently pay dividends.

What is Sana Biotechnology’s EPS estimate?

Sana Biotechnology’s EPS estimate is -0.19.

How many shares outstanding does Sana Biotechnology have?

Sana Biotechnology has 258,702,030 shares outstanding.

What happened to Sana Biotechnology’s price movement after its last earnings report?

Sana Biotechnology reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.201. Following the earnings report the stock price went up 6.507%.

Which hedge fund is a major shareholder of Sana Biotechnology?

Currently, no hedge funds are holding shares in SANA

Sana Biotechnology Stock Smart Score

Outperform

Fundamentals

Return on Equity

-109.12%

Trailing 12-Months

Asset Growth

-41.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sana Biotechnology

Sana Biotechnology (SANA) is a leading biotechnology company focused on developing and delivering engineered cells as medicines for patients. Operating within the biotechnology and pharmaceutical sectors, Sana specializes in advancing in vivo and ex vivo cell engineering platforms with the goal of treating a range of diseases including cancer, genetic disorders, and other serious illnesses. The company's core technologies aim to repair or control genes and replace damaged cells with healthy ones, offering innovative solutions that address unmet medical needs.

Sana Biotechnology (SANA) Earnings & Revenues

Historic Earnings Reports

SANA Stock 12 Month Forecast

Average Price Target

$9.00

▲(83.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.5446153846153843,4.249230769230769,4.953846153846154,5.658461538461538,6.363076923076923,7.067692307692308,7.772307692307693,8.476923076923077,9.181538461538462,9.886153846153846,10.590769230769231,11.295384615384616,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.313846153846154,3.7876923076923075,4.2615384615384615,4.735384615384615,5.2092307692307696,5.683076923076923,6.156923076923077,6.63076923076923,7.104615384615385,7.578461538461538,8.052307692307693,8.526153846153846,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.84,3.006153846153846,3.172307692307692,3.338461538461538,3.5046153846153842,3.6707692307692303,3.836923076923077,4.003076923076923,4.169230769230769,4.335384615384616,4.501538461538461,4.667692307692308,4.833846153846154,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >